Compounds that bind to P185 and methods of using the same

Details Compounds that bind to P185 and methods of using the same Compounds that bind to P185 and methods of using the same

2005-11-17

2010-06-29

Audet, Maury (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

11 to 14 amino acid residues in defined sequence

C514S009100, C514S014800, C514S017400, C514S04400A, C424S001690

Reexamination Certificate

active

07745577

ABSTRACT:
Novel peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents. are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces are disclosed. Methods of treating an individual who has cancer characterized by tumor cells that have a p185 on their cell surfaces are disclosed.

REFERENCES:
patent: 5663144 (1997-09-01), Greene et al.
patent: 5677637 (1997-10-01), Nakazato et al.
patent: 6100377 (2000-08-01), Greene
patent: 6417168 (2002-07-01), Greene et al.
patent: 7179785 (2007-02-01), Greene et al.
patent: WO 99/44645 (1999-09-01), None
Frieden et al., “Adenosine deaminase and adenylate deamnase: comparative kinetic studies with transition state and ground-state analogue inhibitors.”Biochemistry1980,19, 5303-5309.
Igarashi et al., “Specific binding of a synthetic peptide derived from an antibody complementarity determining region to phosphatidylserine.” J.Biochem. (Tokyo) 1995, 117, 452-457.
Laurie et al. “Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins.” J.Biol. Chem. 1997, 272, 30937-30944.
Leysen et al., “The dissociation rate of unlabeled dopamine antagonists and agonists from the dopamine-D2 receptor, application of an original filter method.” J.Recept. Res. 1984, 4, 817-845.
Markgren et al., “Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology.”Anal. Biochem. 2000, 279, 71-78.
McGrath et al., “Crystal structure of human cathepsin K complexed with a potent inhibitor”Nat. Struct. Biol. 1997, 4, 105-109.
Meyer et al., “Backward binding and other structural surprises.”Perspect. Drug Discovery Des. 1995, 3, 168-195.
Padlan et al. “Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex.”Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 5938-5942.
Pargellis et al. “Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer.”Biochemistry, 1994, 33, 12527-12534.
Sautel et al. “Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.” Mol.Pharmacol. 1996, 50, 285-292.
Schwartz, T. W. “Locating ligand-binding sites in 7TM receptors by protein engineering.”Curr. Opin. Blotechnol. 1994, 5, 434-444.
Sheriff et al. “Three-dimensional structure of an antibody-antigen complex.”Proc. Natl. Acad. Sci. U.S.A. 1987, 84,8075-8079.
Sliwkowski et al., (1999) “Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)”,Semin. Oncol., 26:60-70.
Thompson et al. “Design of potent and selective human cathepsin K inhibitors that span the active site.”Proc. Natl. Acad. Sci. U.S.A. 1997, 94,14249-14254.
Turk et al. “Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors.”Biochemistry1995, 34, 4791-4797.
Weiner, (1999) “An overview of monoclonal antibody therapy of cancer”,Seminars in Oncology, 26 (suppl. 12), p. 41-50.
Yamamoto et al. “Refined X-ray structure of papain. E-64-complex at 2.1-A resolution.”J. Biol. Chem. 1991, 266,14771-14777.
Yamashita et al. “Structure and design of potent and selective Cathepsin K Inhibitors.” J.Am. Chem. Soc. 1997, 119, 11351-11352.
Di Blasio, et al., “Noncoded Residues as Building Blocks in the Design of Specific Secondary Structures: Symmetrically Distributed Glycines and β-Alanine”Biopolymers, 1993, p. 1037-1049.
Hruby, V., “Conformational and Topographical Consideration in the Design of Biologically Active Peptides.”Biopolymers, 1993, 33:1073-1082.
Lodato, et al., “Immunohistochemical Evaluation of c-erbB-2 Oncogene Expression in Ductal Carcinoma In Situ and Atypical Ductal Hyperplasia of the Breast.”Modern Pathology, 1990, 3:449-454.
Manning, et al., “Design of Cyclic and Linear Peptide Antagonists of Vasopressin and Oxytocin: Current Status and Future Directions.”Regulatory Peptides, 1993, 45:279-283.
Matsuyama, et al., “A Novel Extracellular Cyclic Lipopeptide which Promotes Flagellum-Dependent and Independent Spreading Growth ofSerratia Marcescens.” Journal of Bacteriology, 174:1769-1776.
Park, B. W. et al. “Rationally Designed anti-HER2
eu peptide mimetic disables PI85HER2
eu tyrosine kinases in vitro and in vivo.”Nat. Biotechnol. 2000, 18, 194-198.
Ripka, A. S.; Rich, D. H. “Peptidomimetic Design.”Curr. Opin. Chem. Biol. 1998, 2, 441-452.
Saragovi, et al., “Design and synthesis of mimetic from an antibody complementarity-determining region.”Science1991, 253, 792-795.
Saragovi and Greene, “Constrained Peptides and Mimetics as Probes of Protein Secondary Structure.”Immunomethods, 1992, 1:5-9.
Wood and Wetzel “Novel Cyclization Chemistry Especially Suited for Biologically Derived, Unprotected Peptides.”,Int. J. Peptide Protein Res., 266:14771-14777.

Affiliated with

Also associated with

Rating

Compounds that bind to P185 and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds that bind to P185 and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds that bind to P185 and methods of using the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4156234